Those results expanded our understanding of the cross talk between immune cells and adipose tissue, indicating that Kdm2a could be a viable epigenetic target for developing more efficacious and cost-effective therapies for the prevention and treatment of obesity and insulin resistance in clinical settings. Here, KDM2A is linked to obesity disorder.